ImaRx grows Q2 revenue, trims losses
ImaRx Therapeutics, a Tucson, Ariz.-based biopharmaceutical company developing and commercializing therapies for vascular disorders, posted a significant increase in revenues while decreasing net losses for its fiscal 2007 second quarter (end-June 30).

For the period, the company reported revenues of approximately $2.2 million, demonstrating robust growth over the $300,000 in revenues recorded for its fiscal 2006 second quarter.

Net loss for the second quarter of 2007 was approximately $1.5 million, a considerable improvement compared with a net loss of approximately $4.1 million for the same period last year.